一例阿达木单抗诱导的 45 岁克罗恩病男性患者的肺炎。
A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn's disease.
机构信息
Department of Medicine, University of British Columbia, Vancouver, British Columbia.
出版信息
Can Respir J. 2011 Sep-Oct;18(5):262-4. doi: 10.1155/2011/713821.
Abstract
Adalimumab is a human monoclonal antibody against tumour necrosis factor-alpha that has been associated with acute lung toxicity, mainly in patients with rheumatoid arthritis. Descriptions of similar patterns of lung injury in patients treated with adalimumab for inflammatory bowel disease are emerging in the literature. A case involving a 45-year-old man with Crohn's disease who developed a nonbronchiolitis inflammatory nodular pattern of lung injury after starting adalimumab is reported.
摘要
阿达木单抗是一种针对肿瘤坏死因子-α的人源单克隆抗体，与急性肺毒性相关，主要发生在类风湿关节炎患者中。文献中也出现了一些接受阿达木单抗治疗炎症性肠病的患者出现类似的肺损伤模式的病例。本文报告了一例 45 岁克罗恩病男性患者，在开始使用阿达木单抗后出现非细支气管炎性炎性结节样肺损伤。
相似文献
1
A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn's disease.
Can Respir J. 2011 Sep-Oct;18(5):262-4. doi: 10.1155/2011/713821.
2
Listeria monocytogenes infection in Crohn's disease treated with adalimumab.
Med J Aust. 2012 Oct 15;197(8):466-7. doi: 10.5694/mja11.10521.
3
Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
J Crohns Colitis. 2013 Oct;7(9):e396. doi: 10.1016/j.crohns.2013.02.011. Epub 2013 Mar 21.
4
Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
J Crohns Colitis. 2011 Dec;5(6):619-22. doi: 10.1016/j.crohns.2011.06.010. Epub 2011 Jul 28.
5
Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease.
World J Gastroenterol. 2015 Feb 21;21(7):2260-2. doi: 10.3748/wjg.v21.i7.2260.
6
Sarcoidosis complicating treatment with adalimumab for Crohn's disease.
J Crohns Colitis. 2014 Sep;8(9):1140-1. doi: 10.1016/j.crohns.2014.02.006. Epub 2014 Mar 13.
7
Adalimumab-induced psoriasis in a patient with Crohn's disease.
Indian J Gastroenterol. 2013 Mar;32(2):135-6. doi: 10.1007/s12664-012-0281-2.
8
[Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
Eksp Klin Gastroenterol. 2013(7):18-22.
9
Hepatitis and pneumonitis during adalimumab therapy in Crohn disease: mind the histoplasmosis!
Arq Gastroenterol. 2014 Jan-Mar;51(1):73-6. doi: 10.1590/s0004-28032014000100015.
10
Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
J Crohns Colitis. 2012 Dec;6(10):1034-7. doi: 10.1016/j.crohns.2012.04.001. Epub 2012 Apr 23.
引用本文的文献
1
Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections.
J Clin Med. 2023 Oct 9;12(19):6419. doi: 10.3390/jcm12196419.
2
Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models.
Arthritis Rheumatol. 2021 May;73(5):769-778. doi: 10.1002/art.41585. Epub 2021 Mar 8.
3
Adalimumab induced interstitial lung disease.
Respir Med Case Rep. 2020 Feb 1;29:101012. doi: 10.1016/j.rmcr.2020.101012. eCollection 2020.
4
A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα.
Inflamm Intest Dis. 2019 May;4(1):35-40. doi: 10.1159/000497778. Epub 2019 Mar 25.
5
Organizing Pneumonia in a Patient with Quiescent Crohn's Disease.
Case Rep Gastrointest Med. 2016;2016:8129864. doi: 10.1155/2016/8129864. Epub 2016 Jun 20.
6
Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease.
World J Gastroenterol. 2015 Feb 21;21(7):2260-2. doi: 10.3748/wjg.v21.i7.2260.
7
Pulmonary manifestations of inflammatory bowel disease.
World J Gastroenterol. 2014 Oct 7;20(37):13501-11. doi: 10.3748/wjg.v20.i37.13501.
8
Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis.
J Bras Pneumol. 2014 Jan-Feb;40(1):77-81. doi: 10.1590/S1806-37132014000100012.
9
Pulmonary manifestations of Crohn's disease.
World J Gastroenterol. 2014 Jan 7;20(1):133-41. doi: 10.3748/wjg.v20.i1.133.
本文引用的文献
1
Postmarketing surveillance of the safety and effectiveness of etanercept in Japan.
J Rheumatol. 2009 May;36(5):898-906. doi: 10.3899/jrheum.080791. Epub 2009 Mar 30.
2
Pulmonary complications of tumor necrosis factor-targeted therapy.
Respir Med. 2009 May;103(5):661-9. doi: 10.1016/j.rmed.2009.01.002. Epub 2009 Feb 7.
3
Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
Medicine (Baltimore). 2007 Jul;86(4):242-251. doi: 10.1097/MD.0b013e3181441a68.
4
Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy.
Am J Med. 2006 Aug;119(8):639-46. doi: 10.1016/j.amjmed.2006.01.015.
5
Interstitial pneumonitis after infliximab therapy for Crohn's disease.
Inflamm Bowel Dis. 2006 May;12(5):427-8. doi: 10.1097/01.MIB.0000219811.54115.aa.
6
Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.
Mod Pathol. 2005 May;18(5):651-5. doi: 10.1038/modpathol.3800333.
7
Noninfectious lung pathology in patients with Crohn's disease.
Am J Surg Pathol. 2003 Feb;27(2):213-9. doi: 10.1097/00000478-200302000-00010.
8
Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.
Eur Respir J. 2000 Feb;15(2):373-81. doi: 10.1034/j.1399-3003.2000.15b25.x.
Zotero 插件